Overview

Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.